MMP9 and prostate carcinoma: The anti-angiogenic activity of genistein is also investigated in prostate cancer, where it downregulates the genes level of uPAR, MMP-9, VEGF, neuropilin, TSP-1, TSP, TGF-β2, BPGF, PAR-2, protease M, and LPA.